Adult growth hormone deficiency
Conditions
Interventions
Sponsors
Huashan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. According to the history, clinical symptoms and signs, insulin tolerance test and imaging examination, those patients who were diagnosed as adult growth hormone deficiency were those who developed adult growth hormone deficiency after 18 years old; The diagnosis of AGHD: for example, the patients after pituitary surgery (2 years after pituitary adenoma surgery, 5 years after craniopharyngioma surgery, 12 years after other pituitary tumors surgery) The peak value of plasma growth hormone in insulin tolerance test was less than 5ng / ml (insulin tolerance test may not be performed in the following cases: anterior pituitary insufficiency, pituitary hormone deficiency more than three kinds, and IGF-1 was lower than the lower limit of normal range, i.e. - 2sd); 2. Male aged 18-50 years; 3. Those who had not used growth hormone for more than one year; 4. Body mass index: 18.5 kg / m2 <= BMI <= 30 kg / m2; 5. When there is a lack of other hormones (such as glucocorticoid, thyroid hormone, sex hormone), the patients should have received the replacement therapy of other hormones, and the treatment dose is stable in the first three months; 6. The subjects are willing and able to cooperate with the scheduled visit, treatment plan, laboratory examination and other test procedures, and sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart disease, including cardiac function grade III or above, severe arrhythmia, unstable angina pectoris or myocardial infarction in the past six months, etc.; 2. Patients with history of ischemic cerebrovascular disease, febrile convulsion and epilepsy; 3. Patients with carpal tunnel syndrome; 4. Patients with poor control of hypertension; 5. Patients with previous or current history of malignant tumor; 6. Patients undergoing antidepressant therapy, immunosuppressive therapy, chemotherapy, radiotherapy (or with a history of radiotherapy); 7. The objects who have used slimming drugs in the past three months; 8. Patients with severe infection; 9. Patients with disturbance of consciousness and psychosis; 10. Subjects with abnormal glucose metabolism; 11. Patients with abnormal liver and kidney function; 12. The patients whose anti HBC, HBsAg and HBeAg were positive by HBV detection; 13. Patients with allergic constitution or allergic to proteins, or allergic to experimental drugs and excipients in this study; 14. Patients who participated in clinical trials of other drugs within three months; 15. Subjects with other mental or physical defects that affect the evaluation of the test drug; 16. If the tumor marker level exceeds the upper limit of the normal range, the researcher will determine whether it is suitable for the clinical trial; 17. Other conditions considered unsuitable by the researchers for inclusion in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Semen analysis;Assessment of erectile function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life assessment;Testicular size; | — |
Countries
China
Contacts
Public ContactZhaoyun Zhang
Huashan Hospital Affiliated to Fudan University
Outcome results
None listed